At the time of writing, Enliven Therapeutics Inc [ELVN] stock is trading at $22.07, up 8.88%. An important factor to consider is whether the stock is rising or falling in short-term value. The ELVN shares have gain 25.18% over the last week, with a monthly amount glided 1.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Enliven Therapeutics Inc [NASDAQ: ELVN] stock has seen the most recent analyst activity on June 16, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $37. Previously, BTIG Research started tracking the stock with Buy rating on December 13, 2024, and set its price target to $42. On September 09, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $37 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $32 on June 11, 2024. Mizuho initiated its recommendation with a Buy and recommended $34 as its price target on April 09, 2024. Jefferies started tracking with a Buy rating for this stock on March 29, 2023, and assigned it a price target of $27.
For the past year, the stock price of Enliven Therapeutics Inc fluctuated between $13.30 and $27.20. Currently, Wall Street analysts expect the stock to reach $52 within the next 12 months. Enliven Therapeutics Inc [NASDAQ: ELVN] shares were valued at $22.07 at the most recent close of the market. An investor can expect a potential return of 135.61% based on the average ELVN price forecast.
Analyzing the ELVN fundamentals
Gross Profit Margin for this corporation currently stands at -0.24% with Operating Profit Margin at -361.52%, Pretax Profit Margin comes in at -317.14%, and Net Profit Margin reading is -317.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.29 and Total Capital is -0.23. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.50 points at the first support level, and at 18.93 for the second support level. However, for the 1st resistance point, the stock is sitting at 22.98, and for the 2nd resistance point, it is at 23.89.
Ratios To Look Out For
It is important to note that Enliven Therapeutics Inc [NASDAQ:ELVN] has a current ratio of 32.95. On the other hand, the Quick Ratio is 32.95, and the Cash Ratio is 7.85.
Transactions by insiders
Recent insider trading involved Patel Anish, CHIEF OPERATING OFFICER, that happened on Nov 07 ’25 when 6667.0 shares were sold. CHIEF SCIENTIFIC OFFICER, Lyssikatos Joseph P completed a deal on Oct 20 ’25 to sell 12500.0 shares. Meanwhile, PRESIDENT AND CEO Kintz Samuel sold 12500.0 shares on Oct 17 ’25.
